NovoNordisk's GLP-1 semaglutide drug, Rybelsus pill FDA approved to reduce heart attacks, strokes, cardiovascular death in type 2 diabetics.

DoctorPodcasts EPISODE 128:#NovoNordisk's #GLP-1 #semaglutide #Rybelsus pill just got FDA approval to cut heart attacks & strokes by 14% in type 2 diabetics. It's the first pill with proven cardiovascular protection! #NovoNordisk's #Wegovy has cardiovascular benefits in non-diabetics above & beyond its weight loss effect. Watch this video podcast interview with expert endocrinologist and diabetes specialist, John Buse, M.D., Ph.D. to get all the details of how you can save your life or increase your #longevity and #healthspan if you have diabetes and/or are overweight or obese.Watch all 128 episodes of the DoctorPodcasts || Cykiert Files video podcast interview show with physicians, scientists, healthcare specialists, entrepreneurs and other experts. Please SUBSCRIBE & FOLLOW @DoctorPodcasts. Please LIKE, REPOST/QUOTE and SHARE the episodes. Send questions, comments and messages to @DoctorPodcasts. Thank you. Robert Cykiert, M.D. #JohnBuseMD#DoctorPodcasts#SELECTTrial#SOULclinicaltrial#SemaglutideCardiovascular#OzempicHeartHealth#WegovyHeartBenefits#GLP1Cardiovascular#SemaglutideHeartAttack#SemaglutideStrokePrevention#MACEreduction#ObesityWithoutDiabetes#CardiovascularRiskReduction#DiabetesPrevention#GLP1ReceptorAgonist#OnceWeeklySemaglutide#NovoNordiskSELECT#HeartDiseaseObesity#WeightLossHeartHealth#EndocrinologyExpert#UNCDiabetesCenter#AmericanDiabetesAssociation#ADA President#GameChangingTrial#OzempicBeyondDiabetes#WegovyBeyondWeightLoss#GLP120Percent#CardiometabolicHealth#PreventiveCardiology#LandmarkTrial2025#SemaglutideScience#DiabetesResearch#ObesityMedicine#HeartFailurePrevention#KidneyProtectionGLP1#FutureOfGLP1#BuseInterview #cykiertfiles #cykiert#RobertCykiertMD#RobertCykiert#videopodcast #heartdisease#heartattack#stroke#cardiovascular#death#diabetes#diabetestype2#t2d#NovoNordisk# GLP-1 #semaglutide # Rybelsus